Atara Biotherapeutics (ATRA) Preferred Stock Liabilities (2013 - 2014)
Atara Biotherapeutics (ATRA) reported Preferred Stock Liabilities of $74.6 million for Q3 2014, up 22.07% quarter-over-quarter from $61.1 million in Q4 2013.
Atara Biotherapeutics (ATRA) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Atara Biotherapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $74.6 million in Q3 2014.
- For the quarter ending Q3 2014, Preferred Stock Liabilities changed N/A year-over-year to $74.6 million; the trailing twelve-month figure through Sep 2014 stood at $74.6 million (changed N/A YoY), and the FY2013 full-year result was $61.1 million, up 3361.25% from the prior year.
- Preferred Stock Liabilities for Q3 2014 stood at $74.6 million, up from $61.1 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $74.6 million in Q3 2014, with the low at $61.1 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Atara Biotherapeutics | 134.61 Mn | 126.21 Mn | 392,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 74.57 Mn |
| Dec 31, 2013 | 61.09 Mn |